New affordable broad-spectrum IV antibiotic launched to treat SA’s critically ill
South African hospitals will be given a wider choice of high-quality generic intravenous (IV) treatments at a much lower cost – the savings of which will benefit not only SA’s struggling healthcare sector but also patients.
Pharma Dynamics – a leading generics distributor in SA has just launched a new IV antibiotic, Sepencil, which will be available to intensivists and physicians to help treat hospitalised patients who are critically ill as a result of bacterial infections.
Elani van Zyl, Antimicrobial Portfolio Manager at Pharma Dynamics says Sepencil combines equal quantities of Imipenem (carbapenem antibiotic) and Cilastatin (dehydropeptidase inhibitor) to produce a powerful antibiotic against pneumonia, sepsis, lower respiratory tract infections, endocarditis, urinary tract infections, bone and joint infections, as well as gynaecological infections.
“The combination of the two compounds have a proven track record spanning more than twenty years, successfully treating millions of patients around the globe.
“Imipenem is part of the carbapenem family of medicines and works by interfering with the bacteria’s cell wall, while Cilastatin blocks the activity of dehydropetidase I, which prevents the breakdown of Imipenem.”
Other benefits include Sepencil ‘s ability to protect the kidneys against potential toxic effects and to reduce the risk of wound sepsis after specific types of surgery. Sepencil is also used to treat mixed infections.
Given its worldwide use, it is rated among the most effective medicines currently in the global healthcare system and features on the World Health Organization’s (WHO) ‘essential medicines’ list.
Sepencil comes in a powder form and once mixed with a solution, it is injected intravenously into a patient’s vein. When administered intravenously, it is usually infused slowly over a period of 20 minutes to one hour every six to eight hours.
It can also be used to treat patients who have a fever and are at high risk of infection due to a low white blood cell count.
“Sepencil is up to 39% more affordable than some competitor brands, which will help hospitals to contain medicine expenditure and realise significant savings”, concludes van Zyl.